This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Li, Z-G Articles by Gao, X-M Search for Related Content PubMed PubMed Citation Articles by Li, Z-G Articles by Gao, X-M Social Bookmarking                         What's this?

T cell vaccination in systemic lupus erythematosus with autologous activated T cells

Department of Rheumatology and Immunology, People’s Hospital, Beijing, China, zgli98{at}yahoo.com

R Mu

Department of Rheumatology and Immunology, People’s Hospital, Beijing, China

Z-P Dai

Department of Immunology, Beijing University Medical School, Beijing, China

X-M Gao

Department of Immunology, Beijing University Medical School, Beijing, China

Systemic lupus erythematosus (SLE) is an autoreactive T cell mediated autoimmune disease. Immunization with inactivated autoreactive T cells may induce idiotype anti-idiotypic reaction to deplete specific subsets of autoreactive T cells involved in SLE. Six SLE patients unsuitable or refused to use immunosuppressants were treated with T cell vaccination. Their clinical manifestations and laboratory parameters including mixed lymphocyte reactions were evaluated. Autoreactive T cell clones were derived from peripheral blood mononuclear cells of the patients and 1 x 10⁷ irradiated T cells were inoculated subcutaneously at 0, two, six and eight weeks, respectively. The enrolled patients were followed up for 32-40 months at an interval of three to six months. The clinical characteristics and laboratory abnormalities improved after inoculation without increasing the dose of corticosteroids and immunosuppressants in most patients. SLE disease activity index (SLEDAI) scores decreased. Proliferative responses against the T cell vaccine were observed in four of six patients. At the time of this report, the six patients remain in clinical remission. No significant side effect from the vaccination was noticed during the follow-up period. The results of this pilot study indicate that T cell vaccination is a safe and effective treatment in SLE.

Key Words: systemic lupus erythematosus • T cell vaccine • therapeutics

Lupus, Vol. 14, No. 11, 884-889 (2005)
DOI: 10.1191/0961203305lu2239oa


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S G O'Neill and D A Isenberg Immunizing patients with systemic lupus erythematosus: a review of effectiveness and safety Lupus, November 1, 2006; 15(11): 778 - 783. [Abstract] [PDF]